nach oben

Erschienen in:

28.01.2022 | Review

The ins and outs of SARS-CoV-2 variants of concern (VOCs)

verfasst von: Mostafa Salehi-Vaziri, Mehdi Fazlalipour, Seyed Mahmood Seyed Khorrami, Kayhan Azadmanesh, Mohammad Hassan Pouriayevali, Tahmineh Jalali, Zabihollah Shoja, Ali Maleki

Erschienen in: Archives of Virology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

SARS-CoV-2, a newly emerging coronavirus that caused the COVID-19 epidemic, has been spreading quickly throughout the world. Despite immunization and some fairly effective therapeutic regimens, SARS-CoV-2 has been ravaging patients, health workers, and the economy. SARS-CoV-2 mutates and evolves to adapt to its host as a result of extreme selection pressure. As a consequence, new SARS-CoV-2 variants have emerged, some of which are classified as variants of concern (VOC) because they exhibit greater transmissibility, cause more-severe disease, are better able to escape immunity, or cause higher mortality than the original Wuhan strain. Here, we introduce these VOCs and review their characteristics, such as transmissibility, immune escape, mortality risk, and diagnostics.

WHO. COVID-19 weekly epidemiological update, 27 July 2021. 2021.

Neerukonda SN, Katneni U (2020) A review on SARS-CoV-2 virology, pathophysiology, animal models, and anti-viral interventions. Pathogens 9(6):426PubMedCentral

Cheng A, Zhang W, Xie Y, Jiang W, Arnold E, Sarafianos SG et al (2005) Expression, purification, and characterization of SARS coronavirus RNA polymerase. Virology 335(2):165–176PubMed

Ferron F, Subissi L, Silveira De Morais AT, Le NTT, Sevajol M, Gluais L et al (2018) Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc Natl Acad Sci 115(2):E162–E171PubMed

Sender R, Bar-On YM, Gleizer S, Bernshtein B, Flamholz A, Phillips R et al (2021) The total number and mass of SARS-CoV-2 virions. Proc Natl Acad Sci 118:25

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines; (April 21, 2020). Available from: https://www.covid19treatmentguidelines.nih.gov/.

Maurin M, Fenollar F, Mediannikov O, Davoust B, Devaux C, Raoult D (2021) Current status of putative animal sources of SARS-CoV-2 infection in humans: wildlife, domestic animals and pets. Microorganisms. 9(4):868PubMedPubMedCentral

Boechat JL, Chora I, Morais A, Delgado L (2021) The immune response to SARS-CoV-2 and COVID-19 immunopathology–current perspectives. Pulmonology. https://doi.org/10.1016/j.pulmoe.2021.03.008CrossRefPubMedPubMedCentral

Focosi D, Maggi F (2021) Neutralising antibody escape of SARS-CoV-2 spike protein: risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Virol. https://doi.org/10.1002/rmv.2231CrossRefPubMedPubMedCentral

10.

Mascola JR, Graham BS, Fauci AS (2021) SARS-CoV-2 viral variants—tackling a moving target. JAMA 325(13):1261–1262PubMed

11.

SARS-CoV-2 Variant Classifications and Definitions23 Sep 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Consequence.

12.

Andrew Rambaut NL, Oliver Pybus, Wendy Barclay, Jeff Barrett, Alesandro Carabelli, Tom Connor, Tom Peacock, David L Robertson, Erik Volz. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations2020. Available from: https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563.

13.

Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al (2020) Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv https://doi.org/10.1101/2020.12.21.20248640

14.

Naveca F, Nascimento V, Souza V, Corado A, Nascimento F, Silva G, et al. Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein. Virological org Available at: https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585. 2021.

15.

B.1.617 variant first identified in India classified as variant of global concern [press release]. ctvnews.ca, 2021

16.

Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK et al (2021) Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. https://doi.org/10.1016/j.cell.2021.04.025CrossRefPubMedPubMedCentral

17.

Gravagnuolo AM, Faqih L, Cronshaw C, Wynn J, Burglin L, Klapper P, et al (2021) Epidemiological investigation of new SARS-CoV-2 variant of concern 202012/01 in England. medRxiv https://doi.org/10.1101/2021.01.14.21249386

18.

Davies NG, Jarvis CI, van Zandvoort K, Clifford S, Sun FY, Funk S, et al (2021) Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 593(7858):270–4

19.

Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al (2021) Transmission of SARS-CoV-2 Lineage B. 1.1. 7 in England: Insights from linking epidemiological and genetic data. medRxiv. https://doi.org/10.1101/2020.12.30.20249034

20.

Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T et al (2021) Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study. Lancet Public Health. https://doi.org/10.1016/S2468-2667(21)00055-4CrossRefPubMedPubMedCentral

21.

Mahase E (2021) Covid-19: Sore throat, fatigue, and myalgia are more common with new UK variant. BMJ. https://doi.org/10.1136/bmj.n288CrossRefPubMed

22.

Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z et al (2021) Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2. BioRxiv. https://doi.org/10.1101/2021.02.14.431117CrossRefPubMedPubMedCentral

23.

Tada T, Dcosta BM, Samanovic-Golden M, Herati RS, Cornelius A, Mulligan MJ, et al (2021) Neutralization of viruses with European, South African, and United States SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA vaccine-elicited antibodies. bioRxiv https://doi.org/10.1101/2021.02.05.430003

24.

Ascoli CA (2021) Could mutations of SARS-CoV-2 suppress diagnostic detection? Nat Biotechnol 39(3):274–275PubMed

25.

Wise J (2021) Covid-19: The E484K mutation and the risks it poses. BMJ. https://doi.org/10.1136/bmj.n359CrossRefPubMed

26.

Makowski L, Olson-Sidford W, Weisel J (2021) Biological and clinical consequences of integrin binding via a rogue RGD motif in the SARS CoV-2 spike protein. Viruses 13(2):146PubMedPubMedCentral

27.

Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A et al (2021) Emergence of SARS-CoV-2 b. 1.1. 7 lineage—united states, December 29, 2020–January 12, 2021. Morbid Mortal Week Rep 70(3):95

28.

Pereira F (2021) SARS-CoV-2 variants combining spike mutations and the absence of ORF8 may be more transmissible and require close monitoring. Biochem Biophys Res Commun 550:8–14PubMedPubMedCentral

29.

Ramírez JD, Muñoz M, Patiño LH, Ballesteros N, Paniz-Mondolfi A (2021) Will the emergent SARS-CoV2 B. 1.1. 7 lineage affect molecular diagnosis of COVID-19? J Med Virol 93(5):2566–2568PubMed

30.

Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J et al (2021) Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592(7854):438–443PubMed

31.

Peñarrubia L, Ruiz M, Porco R, Rao SN, Juanola-Falgarona M, Manissero D et al (2020) Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak. Int J Infect Dis 97:225–229PubMedPubMedCentral

32.

Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM et al (2021) Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera. Cell. 184(9):2348-23461.e6PubMedPubMedCentral

33.

Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. (2020) Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv https://doi.org/10.1101/2020.12.21.20248640

34.

Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y et al (2021) Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. Nature. 593(7857):130–135PubMed

35.

Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DdS, Mishra S et al (2021) Genomics and epidemiology of the P 1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372(6544):815–821PubMedPubMedCentral

36.

Freitas AR, Lemos DR, Beckedorff OA, Cavalcante LP, Siqueira AM, Mello RC, et al. (2021) The increase in the risk of severity and fatality rate of covid-19 in southern Brazil after the emergence of the Variant of Concern (VOC) SARS-CoV-2 P. 1 was greater among young adults without pre-existing risk conditions. medRxiv https://doi.org/10.1101/2021.04.13.21255281

37.

Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al (2021) Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372(6544):815–21PubMedPubMedCentral

38.

Hirotsu Y, Omata M (2021) Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring K417T/E484K/N501Y mutations in Kofu, Japan. J Infect. 82(6):276–316PubMedPubMedCentral

39.

Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G et al (2021) Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 29(5):747–751PubMedPubMedCentral

40.

Lamarca AP, de Almeida LG, da Silva Francisco R, Lima LFA, Scortecci KC, Perez VP, et al. (2021) Genomic surveillance of SARS-CoV-2 tracks early interstate transmission of P. 1 lineage and diversification within P. 2 clade in Brazil. medRxiv. https://doi.org/10.1101/2021.03.21.21253418

41.

Resende PC, Delatorre E, Gräf T, Mir D, Motta FC, Appolinario LR et al (2020) Evolutionary dynamics and dissemination pattern of the SARS-CoV-2 lineage B. 1.1. 33 during the early pandemic phase in Brazil. Front Microbiol. https://doi.org/10.3389/fmicb.2020.615280CrossRefPubMed

42.

Lopez-Rincon A, Perez-Romero C, Tonda A, Mendoza-Maldonado L, Claassen E, Garssen J, et al (2021) Design of specific primer sets for the detection of B. 1.1. 7, B. 1.351 and P. 1 SARS-CoV-2 variants using deep learning. bioRxiv https://doi.org/10.1101/2021.01.20.427043

43.

Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M et al (2021) Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv. https://doi.org/10.1101/2021.04.22.440932CrossRef

44.

Organization WH (2021) COVID-19 weekly epidemiological update, 9 May 2021

45.

Organization WH (2021) COVID-19 weekly epidemiological update, edition 42, 01 June 2021

46.

Ranjan R, Sharma A, Verma MK (2021) Characterization of the second wave of COVID-19 in India. medRxiv. https://doi.org/10.1101/2021.04.17.21255665

47.

England PH (2021) SARS-CoV-2 variants of concern and variants under investigation in England. Techn Brief 16

48.

Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L et al (2021) Assessing transmissibility of SARS-CoV-2 lineage B117 in England. Nature 593(7858):266–269PubMed

49.

European Centre for Disease Prevention and Control (2021) Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA. First update – 21 January. ECDC: Stockholm

50.

WHO (2021) Weekly epidemiological update on COVID-19. 13 April 2021

51.

Ong SWX, Young BE, Lye DC (2021) Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(21)00201-2CrossRefPubMedPubMedCentral

52.

Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD et al (2021) Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England. Science. 372:6538

53.

Leung K, Shum MH, Leung GM, Lam TT, Wu JT (2021) Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Eurosurveillance 26(1):2002106PubMedCentral

54.

Davies NG, Jarvis CI, van Zandvoort K, Clifford S, Sun FY, Funk S et al (2021) Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 593(7858):270–274PubMed

55.

Schuit M, Biryukov J, Beck K, Yolitz J, Bohannon J, Weaver W, et al (2021) The stability of an isolate of the SARS-CoV-2 B.1.1.7 lineage in aerosols is similar to three earlier isolates. J Infect Dis

56.

Liu Y, Liu J, Plante KS, Plante JA, Xie X, Zhang X, et al (2021) The N501Y spike substitution enhances SARS-CoV-2 transmission. bioRxiv. https://doi.org/10.1101/2021.03.08.434499CrossRefPubMedPubMedCentral

57.

Johnson BA, Xie X, Bailey AL, Kalveram B, Lokugamage KG, Muruato A et al (2021) Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature 591(7849):293–299PubMedPubMedCentral

58.

Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, et al (2021) SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity. bioRxiv https://doi.org/10.1101/2021.06.17.448820CrossRefPubMedPubMedCentral

59.

Felipe N, Valdinete N, Victor S, André C, Fernanda N, George S, et al (2021) Nature Portfolio

60.

Naveca F, Nascimento V, Souza V, Corado A, Nascimento F, Silva G, et al (2021) COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P. 1.

61.

Coutinho RM, Marquitti FMD, Ferreira LS, Borges ME, da Silva RLP, Canton O, et al (2021) Model-based evaluation of transmissibility and reinfection for the P 1 variant of the SARS-CoV-2. medRxiv https://doi.org/10.1101/2021.03.03.21252706

62.

Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al (2021) Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil. medRxiv

63.

Nelson G, Buzko O, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P (2021) Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. bioRxiv https://doi.org/10.1101/2021.01.13.426558

64.

Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE (2021) SARS-CoV-2 variants of concern are emerging in India. Nature Med 27:1131–1133PubMed

65.

gov.wales. Technical Advisory Group: advice from TAG and the Chief Scientific Advisor for Health on the Delta Variant (18 June 2021). Available from: https://gov.wales/technical-advisory-group-advice-tag-and-chief-scientific-advisor-health-delta-variant.

66.

Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L (2021) Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 372:n579PubMed

67.

Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, et al (2021) Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv https://doi.org/10.1101/2021.03.07.21252647

68.

McCallum M, Bassi J, Marco A, Chen A, Walls AC, Iulio JD, et al (2021) SARS-CoV-2 immune evasion by variant B1427/B1429. bioRxiv. https://doi.org/10.1101/2021.03.31.437925

69.

Ferreira I, Datir R, Papa G, Kemp S, Meng B, Rakshit P, et al (2021) SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies. bioRxiv https://doi.org/10.1101/2021.05.08.443253

70.

Yadav PD, Mohandas S, Shete AM, Nyayanit DA, Gupta N, Patil DY, et al (2021) SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant. bioRxiv. https://doi.org/10.1101/2021.05.05.442760

71.

Control ECfDPa. Emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA. ECDC: Stockholm. 11 May 2021

72.

Cele S, Gazy I, Jackson L, Hwa S-H, Tegally H, Lustig G, et al (2021) Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. medRxiv https://doi.org/10.1101/2021.01.26.21250224

73.

Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K et al (2020) Seasonal coronavirus protective immunity is short-lasting. Nat Med 26(11):1691–1693PubMed

74.

Aldridge R, Lewer D, Beale S, Johnson A, Zambon M, Hayward A, et al (2020) Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study [version 2; peer review: 2 approved]. Welcome Open Res https://doi.org/10.12688/wellcomeopenres.15812.2

75.

McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarthy LR, Bain WG, Haidar G et al (2021) Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science 371(6534):1139–1142PubMedPubMedCentral

76.

Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J et al (2021) COVID-19-neutralizing antibodies predict disease severity and survival. Cell 184(2):476–88.e11PubMed

77.

Garcia-Beltran WF, Lam EC, St. Denis K, Nitido AD, Garcia ZH, Hauser BM, et al (2021) Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. https://doi.org/10.1016/j.cell.2021.03.013CrossRefPubMedPubMedCentral

78.

Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J et al (2021) SARS-CoV-2 variant B117 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe 29(4):529–539PubMedPubMedCentral

79.

Muik A, Wallisch AK, Sänger B, Swanson KA, Mühl J, Chen W et al (2021) Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 371(6534):1152–1153PubMedPubMedCentral

80.

Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GBE, et al (2021) mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv https://doi.org/10.1101/2021.01.25.427948

81.

Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS et al (2021) SARS-CoV-2 variants B1351 and P1 escape from neutralizing antibodies. Cell. https://doi.org/10.1016/j.cell.2021.03.036CrossRefPubMedPubMedCentral

82.

Edara VV, Norwood C, Floyd K, Lai L, Davis-Gardner ME, Hudson WH et al (2021) Infection- and vaccine-induced antibody binding and neutralization of the B1351 SARS-CoV-2 variant. Cell Host Microbe. https://doi.org/10.1016/j.chom.2021.03.009CrossRefPubMedPubMedCentral

83.

Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM et al (2021) Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. https://doi.org/10.1016/j.cell.2021.02.037CrossRefPubMedPubMedCentral

84.

Dong J, Zost SJ, Greaney AJ, Starr TN, Dingens AS, Chen EC, et al (2021) Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv. https://doi.org/10.1101/2021.01.27.428529

85.

Wang P, Liu L, Iketani S, Luo Y, Guo Y, Wang M, et al (2021) Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv https://doi.org/10.1016/j.chom.2021.04.007

86.

Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B et al (2021) SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature Med 27(4):622–625PubMed

87.

McCallum M, Bassi J, Marco AD, Chen A, Walls AC, Iulio JD, et al (2021) SARS-CoV-2 immune evasion by variant B1427/B1429. bioRxiv https://doi.org/10.1101/2021.03.31.437925

88.

Shen X, Tang H, Pajon R, Smith G, Glenn GM, Shi W et al (2021) Neutralization of SARS-CoV-2 Variants B1429 and B1351. New Engl J Med. https://doi.org/10.1056/NEJMc2103740CrossRefPubMed

89.

Tchesnokova V, Kulakesara H, Larson L, Bowers V, Rechkina E, Kisiela D, et al (2021) Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. bioRxiv https://doi.org/10.1101/2021.02.22.432189

90.

Jacobson KB, Pinsky BA, Rath MEM, Wang H, Miller JA, Skhiri M, et al (2021) Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center. medRxiv. https://doi.org/10.1101/2021.04.14.21255431

91.

Javanmardi K, Chou C-W, Terrace CI, Annapareddy A, Kaoud TS, Guo Q, et al (2021) Rapid characterization of spike variants via mammalian cell surface display. bioRxiv. https://doi.org/10.1101/2021.03.30.437622.

92.

Edara V-V, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. (2021) Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv. https://doi.org/10.1101/2021.05.09.443299

93.

Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, et al. (2021) Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. bioRxiv. https://doi.org/10.1101/2021.04.23.441101

94.

Callaway E, Mallapaty S (2021) Novavax offers first evidence that COVID vaccines protect people against variants. Nature 590(7844):17PubMed

95.

Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S et al (2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 397(10282):1351–1362PubMedPubMedCentral

96.

Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. (2021) Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv. https://doi.org/10.1101/2021.06.28.21259420

97.

Lefèvre B, Tondeur L, Madec Y, Grant R, Lina B, van der Werf S, et al. (2021) Impact of B.1.351 (beta) SARS-CoV-2 variant on BNT162b2 mRNA vaccine effectiveness in long-term care facilities of eastern France: a retrospective cohort study. medRxiv. https://doi.org/10.1101/2021.07.28.21261285

98.

Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR et al (2021) mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nature Med 27(9):1614–21PubMed

99.

Seppälä E, Veneti L, Starrfelt J, Danielsen AS, Bragstad K, Hungnes O et al (2021) Vaccine effectiveness against infection with the Delta (B 1617 2) variant, Norway, April to August 2021. Euro Surveill 26(35):2100793PubMedCentral

100.

González S, Olszevicki S, Salazar M, Calabria A, Regairaz L, Marín L et al (2021) Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60–79: a retrospective cohort study in Argentina. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2021.101126CrossRefPubMedPubMedCentral

101.

Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, et al (2021) Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants. bioRxiv https://doi.org/10.1101/2021.02.25.432969

102.

Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V et al (2020) Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369(6506):1014–1018PubMed

103.

Becker M, Dulovic A, Junker D, Ruetalo N, Kaiser PD, Pinilla YT et al (2021) Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. Nat Commun 12(1):3109PubMedPubMedCentral

104.

Hoffmann M, Hofmann-Winkler H, Krüger N, Kempf A, Nehlmeier I, Graichen L, et al. (2021) SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. bioRxiv. https://doi.org/10.1101/2021.05.04.442663

105.

Rathnasinghe R, Jangra S, Cupic A, Martínez-Romero C, Mulder LC, Kehrer T et al (2021) The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. MedRxiv. https://doi.org/10.1101/2021.01.19.21249592CrossRefPubMedPubMedCentral

106.

Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR et al (2021) Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nature Med 27(4):620–621PubMed

107.

Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA et al (2021) Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med 27(4):717–726PubMedPubMedCentral

108.

Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE et al (2021) Serum neutralizing activity elicited by mRNA-1273 vaccine. New Engl J Med 384(15):1468–1470PubMed

109.

Resende PC, Bezerra JF, de Vasconcelos RHT, Arantes I, Appolinario L, Mendonça AC, et al. (2021) Spike E484K mutation in the first SARS-CoV-2 reinfection case confirmed in Brazil, 2020. Virological 10

110.

Nonaka CK, Franco MM, Gräf T, de Lorenzo Barcia CA, de Ávila Mendonça RN, de Sousa KAF et al (2021) Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil. Emerg Infect Dis. 27(5):1522-1524PubMedPubMedCentral

111.

Naveca F, da Costa C, Nascimento V, Souza V, Corado A, Nascimento F, et al. (2021) SARS-CoV-2 reinfection by the new Variant of Concern (VOC) P. 1 in Amazonas, Brazil. virological org Preprint available at: https://virological.org/t/sars-cov-2-reinfection-by-thenew-variant-of-concern-voc-p-1-in-amazonas-brazil/596 Available at: https://virological.org/t/sars-cov-2-reinfection-by-the-new-variant-of-concern-voc-p-1-in-amazonas-brazil/596

112.

Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN et al (2021) Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29(1):44-57.e9PubMedPubMedCentral

113.

Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva FA, Wojcechowskyj JA et al (2021) Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell 184(5):1171–87.e20PubMedPubMedCentral

114.

Williams TC, Burgers WA (2021) SARS-CoV-2 evolution and vaccines: cause for concern? Lancet Respir Med 9(4):333–335PubMedPubMedCentral

115.

Motozono C, Toyoda M, Zahradnik J, Ikeda T, Saito A, Tan TS, et al. (2021) An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity. bioRxiv. https://doi.org/10.1101/2021.04.02.438288.

116.

Geers D, Shamier MC, Bogers S, Hartog Gd, Gommers L, Nieuwkoop NN, et al. (2021) SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. Sci Immunol 6(59):eabj1750

117.

Jung JH, Rha M-S, Sa M, Choi HK, Jeon JH, Seok H et al (2021) SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells. Nat Commun 12(1):4043PubMedPubMedCentral

118.

Kasuga Y, Zhu B, Jang K-J, Yoo J-S (2021) Innate immune sensing of coronavirus and viral evasion strategies. Exp Mol Med 53(5):723–736PubMedPubMedCentral

119.

Zhang Q, Bastard P, Liu Z, Pen JL, Moncada-Velez M, Chen J, et al. (2020)Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 370(6515):eabd4570

120.

van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S et al (2020) Presence of genetic variants among young men with severe COVID-19. JAMA 324(7):663–673PubMed

121.

Yang Z, Zhang X, Wang F, Wang P, Kuang E, Li X (2020) Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2. bioRxiv. https://doi.org/10.1101/2020.08.12.247767

122.

Jiang H-w, Zhang H-n, Meng Q-f, Xie J, Li Y, Chen H et al (2020) SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70. Cell Mol Immunol 17(9):998–1000PubMed

123.

Mu J, Fang Y, Yang Q, Shu T, Wang A, Huang M et al (2020) SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2. Cell Discovery. 6(1):1–4

124.

Zheng Y, Zhuang M-W, Han L, Zhang J, Nan M-L, Zhan P et al (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. Signal Transduct Target Ther 5(1):1–13

125.

Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH (2021) (2021) Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 593(7858):270–274PubMed

126.

Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G (2020) Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol 35(12):1123–1138PubMedPubMedCentral

127.

Holmes L Jr, Enwere M, Williams J, Ogundele B, Chavan P, Piccoli T et al (2020) Black-white risk differentials in COVID-19 (SARS-COV2) Transmission, mortality and case fatality in the United States: translational epidemiologic perspective and challenges. Int J Environ Res Public Health. 17(12):4322PubMedCentral

128.

Paredes MI, Lunn S, Famulare M, Frisbie LA, Painter I, Burstein R, et al. (2021) Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study. medRxiv https://doi.org/10.1101/2021.09.29.21264272

129.

Sheikh A, McMenamin J, Taylor B, Robertson C (2021) SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397(10293):2461–2462PubMedPubMedCentral

130.

England PH (2021) SARS-CoV-2 variants of concern and variants under investigation in England. Techn Brief

131.

Ong SWX, Chiew CJ, Ang LW, Mak T-M, Cui L, Toh MPH, et al (2021) Clinical and virological features of SARS-CoV-2 variants of concern: a retrospective cohort study comparing B. 1.1. 7 (Alpha), B. 1.315 (Beta), and B. 1.617. 2 (Delta)

132.

Walensky RP, Walke HT, Fauci AS (2021) SARS-CoV-2 variants of concern in the United States—Challenges and opportunities. JAMA 325(11):1037–1038PubMedPubMedCentral

133.

Guo S, Liu K, Zheng J (2021) The genetic variant of SARS-CoV-2: would It matter for controlling the devastating pandemic? Int J Biol Sci 17(6):1476PubMedPubMedCentral

134.

Abdool Karim SS, de Oliveira T (2021) New SARS-CoV-2 variants—clinical, public health, and vaccine implications. New Engl J Med 384(19):1866–1868PubMed

135.

Organization WH (2021) Methods for the detection and identification of SARS-CoV-2 variants, March 2021. World Health Organization, Regional Office for Europe

136.

Organization WH (2021) Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health, 8 January 2021

137.

Landis J, Moorad R, Pluta LJ, Caro-Vegas C, McNamara RP, Eason AB, et al (2021) Intra-host evolution provides for continuous emergence of SARS-CoV-2 variants. medRxiv

138.

Food U, Administration D (2021) Genetic Variants of SARS-CoV-2 May Lead to False Negative Results with Molecular Tests for Detection of SARS-CoV-2-Letter to Clinical Laboratory Staff and Health Care Providers.[updated 8 January 2021

139.

Vogels CB, Breban M, Alpert T, Petrone ME, Watkins AE, Hodcroft E, et al. (2021) PCR assay to enhance global surveillance for SARS-CoV-2 variants of concern. medRxiv https://doi.org/10.1101/2021.01.28.21250486

140.

Korukluoglu G, Kolukirik M, Bayrakdar F, Ozgumus GG, Altas AB, Cosgun Y, et al. (2021) 40 minutes RT-qPCR Assay for Screening Spike N501Y and HV69-70del Mutations. bioRxiv https://doi.org/10.1101/2021.01.26.428302

141.

Perchetti GA, Zhu H, Mills MG, Shrestha L, Wagner C, Bakhash SM, et al. (2021) Specific allelic discrimination of N501Y and other SARS-CoV-2 mutations by ddPCR detects B 11 7 lineage in Washington State. medRxiv https://doi.org/10.1101/2021.03.10.21253321

142.

Courjon J-V, Contenti J, Demonchy E, Levraut J, Barbry P, Rios G, et al. (2021) Spread of the SARS-CoV-2 UK-variant in the South East of France: impact on COVID-19 patients age, comorbidity profiles and clinical presentation, week 50 2020 to week 8 2021. medRxiv

143.

Wang H, Miller J, Verghese M, Sibai M, Solis D, Mfuh KO, et al. (2021) Multiplex SARS-CoV-2 Genotyping PCR for Population-Level Variant Screening and Epidemiologic Surveillance. medRxiv

144.

Banada PP, Green R, Banik S, Chopoorian A, Streck D, Jones R, et al. (2021) A Simple RT-PCR Melting temperature Assay to Rapidly Screen for Widely Circulating SARS-CoV-2 Variants. medRxiv

145.

Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M et al (2021) Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveill 26(16):2100348PubMedCentral

146.

Bodin K, Rocklov J (2021) Inherent random fluctuations in COVID-19 outbreaks may explain rapid growth of new mutated virus variants. medRxiv

147.

Sabino EC, Buss LF, Carvalho MP, Prete CA, Crispim MA, Fraiji NA et al (2021) Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. The Lancet 397(10273):452–455

148.

Eguia RT, Crawford KHD, Stevens-Ayers T, Kelnhofer-Millevolte L, Greninger AL, Englund JA et al (2021) A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog. 17(4):e1009453PubMedPubMedCentral

149.

Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC et al (2020) Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 9:e61312PubMedPubMedCentral

150.

Mullard A (2020) How COVID vaccines are being divvied up around the world. Nature

151.

Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D (2021) SARS-CoV-2 variants and ending the COVID-19 pandemic. The Lancet 397(10278):952–954

152.

Racaniello V. Is there a limit to how much the coronavirus can mutate? livescience.com, February 11, 2021.

153.

Moore JP (2021) Approaches for optimal use of different COVID-19 vaccines: issues of viral variants and vaccine efficacy. JAMA 325(13):1251–1252PubMed

154.

Meera Chand SH (2020) Gavin Dabrera, Christina Achison, Wendy Barclay, Neil Ferguson, Erik Volz, Nick Loman, Andrew Rambaut, Jeff Barrett Investigation of novel SARS-COV-2 variant Variant of Concern 202012/01. Public Health England, England

155.

Andrew Rambaut NL, Oliver Pybus, Wendy Barclay, Jeff Barrett, Alesandro Carabelli, Tom Connor, Tom Peacock, David L Robertson, Erik Volz (2020) Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

156.

Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M et al (2021) SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. Microorganisms. 9(7):1542PubMedPubMedCentral

157.

Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS et al (2021) SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe 29(7):1124–36.e11PubMedPubMedCentral

158.

Chen J, Wang R, Wang M, Wei G-W (2020) Mutations Strengthened SARS-CoV-2 Infectivity. J Mol Biol 432(19):5212–5226PubMedPubMedCentral

159.

Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al (2020) Evolution of antibody immunity to SARS-CoV-2. bioRxiv https://doi.org/10.1101/2020.11.03.367391

160.

Nonaka CK, Franco MM, Gräf T, de Lorenzo Barcia CA, de Ávila Mendonça RN, De Sousa KAF et al (2021) Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil. Emerg Infect Dis 27(5):1522PubMedPubMedCentral

161.

Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY et al (2021) Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29(3):463–76.e6PubMedPubMedCentral

162.

Andreano E, Piccini G, Licastro D, Casalino L, Johnson NV, Paciello I, et al. (2020) SARS-CoV-2 escape <em>in vitro</em> from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. https://doi.org/10.1101/2020.12.28.424451

163.

Zhang L, Jackson CB, Mou H, Ojha A, Peng H, Quinlan BD et al (2020) SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun 11(1):6013PubMedPubMedCentral

164.

Johnson BA, Xie X, Kalveram B, Lokugamage KG, Muruato A, Zou J, et al. (2020) Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis. bioRxiv https://doi.org/10.1101/2020.08.26.268854

165.

Haynes WA, Kamath K, Lucas C, Shon J, Iwasaki A. (2021) Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes. medRxiv. https://doi.org/10.1101/2021.01.06.20248960.

Titel: The ins and outs of SARS-CoV-2 variants of concern (VOCs)
verfasst von: Mostafa Salehi-Vaziri
Mehdi Fazlalipour
Seyed Mahmood Seyed Khorrami
Kayhan Azadmanesh
Mohammad Hassan Pouriayevali
Tahmineh Jalali
Zabihollah Shoja
Ali Maleki
Publikationsdatum: 28.01.2022
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 2/2022
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-022-05365-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2022

Infectivity and antigenicity of pseudoviruses with high-frequency mutations of SARS-CoV-2 identified in Portugal

Novel adenovirus associated with common tern (Sterna hirundo) chicks

Establishment of five new genera in the family Geminiviridae: Citlodavirus, Maldovirus, Mulcrilevirus, Opunvirus, and Topilevirus

Pathogenicity and genome-wide sequence analysis reveals relationships between soybean mosaic virus strains

Complete genome sequences of two isolates of spiraea yellow leafspot virus (genus Badnavirus) from Spiraea x bumalda ‘Anthony Waterer’